However, considering specific CRC predictive biomarkers, the resistance to 5FU and many other CRC drugs can be overcomed by the use of targeted therapies including bevacizumab as the first-line anti-vascular endothelial growth factor-A (anti-VEGF-A) drug. The gene discussed is VEGFA; the disease is colorectal carcinoma.